Evolent Health, Inc. (NYSE:EVH) Position Lessened by Values First Advisors Inc.

Values First Advisors Inc. decreased its stake in Evolent Health, Inc. (NYSE:EVH) by 11.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,656 shares of the technology company’s stock after selling 2,018 shares during the period. Values First Advisors Inc.’s holdings in Evolent Health were worth $517,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in EVH. ICA Group Wealth Management LLC bought a new stake in shares of Evolent Health in the 4th quarter worth approximately $32,000. Captrust Financial Advisors boosted its position in Evolent Health by 254.4% during the 2nd quarter. Captrust Financial Advisors now owns 1,758 shares of the technology company’s stock worth $54,000 after acquiring an additional 1,262 shares during the period. Tower Research Capital LLC TRC boosted its position in Evolent Health by 75.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,777 shares of the technology company’s stock worth $103,000 after acquiring an additional 1,626 shares during the period. West Tower Group LLC acquired a new position in Evolent Health during the 2nd quarter worth $124,000. Finally, Nisa Investment Advisors LLC boosted its position in Evolent Health by 389.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,035 shares of the technology company’s stock worth $137,000 after acquiring an additional 4,006 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on EVH shares. JMP Securities boosted their price target on Evolent Health from $37.00 to $38.00 and gave the stock a “market outperform” rating in a research report on Friday, February 23rd. William Blair reissued an “outperform” rating on shares of Evolent Health in a research note on Tuesday, January 9th. Canaccord Genuity Group dropped their price objective on Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. dropped their price objective on Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Friday, March 15th. Finally, Oppenheimer initiated coverage on Evolent Health in a research note on Friday, March 1st. They issued an “outperform” rating and a $45.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.70.

Evolent Health Stock Up 0.2 %

Shares of EVH traded up $0.06 during trading hours on Thursday, hitting $32.79. 830,006 shares of the company were exchanged, compared to its average volume of 989,808. The company has a market cap of $3.78 billion, a PE ratio of -25.78 and a beta of 1.54. The firm’s 50 day moving average is $31.82 and its 200-day moving average is $29.72. Evolent Health, Inc. has a 52 week low of $23.33 and a 52 week high of $36.70. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.01.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.13. The business had revenue of $556.06 million during the quarter, compared to analysts’ expectations of $541.87 million. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. On average, equities research analysts forecast that Evolent Health, Inc. will post 0.87 EPS for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.